Our results confirmed that ASC-exos promoted the TOX, CD4, and LYZ1 expression and inhibited the Mettl7b and Serpinb2 expression in breast cancer tumors, which were significantly enriched in the Human T-cell leukemia virus 1 infection pathway. The gene discussed is TMT1B; the disease is breast carcinoma.